Quality of Life and Its Association with Androgenetic Alopecia Patients in Shanghai: A Cross-Sectional Study.
Hairdex
WHO-BREF
androgenetic alopecia
quality of life
Journal
Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
10
2022
accepted:
22
12
2022
entrez:
4
1
2023
pubmed:
5
1
2023
medline:
5
1
2023
Statut:
epublish
Résumé
Health-related quality of life (HRQoL) of androgenetic alopecia patients has become increasingly important, but the influencing factors associated with the different domains are poorly understood. This study aimed to investigate the influencing factors in HRQoL of androgenetic alopecia patients and identify its strongly associated domains. We enrolled 170 androgenetic alopecia patients. HRQoL was measured using the World Health Organization Quality of Life Brief Version (WHO-BREF), and Hairdex. HRQoL was significantly impaired in patients <30 years, (WHO-BREF: P=0.022, Hairdex: P=0.004), less educated (WHO-BREF: P=0.021, Hairdex: P=0.003), single patients (Hairdex: P=0.023), and urban residence (Hairdex: P=0.043). By domains, those <30 years were impaired by physical health (P=0.038) and psychological (P=0.030) by WHO-BREF, and symptoms (P=0.002) and emotions (P=0.002) by Hairdex. Singles were impaired by symptoms (P=0.020), and emotions (P=0.009) by Hairdex. Less-educated individuals had impaired all domains in the WHO-BREF and Hairdex, except for physical health. Women had impaired symptoms (P=0.013) and stigmatization (P=0.041) in Hairdex. Androgenetic alopecia is associated with significantly reduced HRQoL in young, less educated, and single patients. Dermatologists should inquire about Quality of Life and appropriately support androgenetic alopecia patients.
Sections du résumé
Background
UNASSIGNED
Health-related quality of life (HRQoL) of androgenetic alopecia patients has become increasingly important, but the influencing factors associated with the different domains are poorly understood.
Objective
UNASSIGNED
This study aimed to investigate the influencing factors in HRQoL of androgenetic alopecia patients and identify its strongly associated domains.
Patients and Methods
UNASSIGNED
We enrolled 170 androgenetic alopecia patients. HRQoL was measured using the World Health Organization Quality of Life Brief Version (WHO-BREF), and Hairdex.
Results
UNASSIGNED
HRQoL was significantly impaired in patients <30 years, (WHO-BREF: P=0.022, Hairdex: P=0.004), less educated (WHO-BREF: P=0.021, Hairdex: P=0.003), single patients (Hairdex: P=0.023), and urban residence (Hairdex: P=0.043). By domains, those <30 years were impaired by physical health (P=0.038) and psychological (P=0.030) by WHO-BREF, and symptoms (P=0.002) and emotions (P=0.002) by Hairdex. Singles were impaired by symptoms (P=0.020), and emotions (P=0.009) by Hairdex. Less-educated individuals had impaired all domains in the WHO-BREF and Hairdex, except for physical health. Women had impaired symptoms (P=0.013) and stigmatization (P=0.041) in Hairdex.
Conclusion
UNASSIGNED
Androgenetic alopecia is associated with significantly reduced HRQoL in young, less educated, and single patients. Dermatologists should inquire about Quality of Life and appropriately support androgenetic alopecia patients.
Identifiants
pubmed: 36597520
doi: 10.2147/CCID.S393633
pii: 393633
pmc: PMC9805703
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2883-2893Informations de copyright
© 2022 Moorthy et al.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest in this work.
Références
Patient Prefer Adherence. 2017 Jan 27;11:151-155
pubmed: 28203058
Psychol Med. 1998 May;28(3):551-8
pubmed: 9626712
Int J Gen Med. 2012;5:633-42
pubmed: 22866015
Int J Trichology. 2019 Jul-Aug;11(4):147-152
pubmed: 31523105
An Bras Dermatol. 2018 Sep-Oct;93(5):651-658
pubmed: 30156613
Ann Dermatol. 2012 Aug;24(3):311-8
pubmed: 22879715
J Clin Aesthet Dermatol. 2018 Jul;11(7):32-35
pubmed: 30057663
J Eur Acad Dermatol Venereol. 2007 Apr;21(4):473-9
pubmed: 17373973
Ann Dermatol. 2018 Jun;30(3):388-391
pubmed: 29853767
Hautarzt. 2001 Mar;52(3):219-27
pubmed: 11284067
J Am Acad Dermatol. 2004 Aug;51(2):189-99
pubmed: 15280836
Int J Trichology. 2010 Jul;2(2):81-5
pubmed: 21712908
Ann N Y Acad Sci. 1951 Mar;53(3):708-28
pubmed: 14819896
Psychol Health Med. 2008 May;13(3):313-25
pubmed: 18569899
J Am Acad Dermatol. 2019 Jun;80(6):1497-1506
pubmed: 30312644
J Dtsch Dermatol Ges. 2015 Feb;13(2):137-42
pubmed: 25597233
G Ital Dermatol Venereol. 2013 Jun;148(3):255-61
pubmed: 23670062
Br J Dermatol. 2009 Aug;161(2):289-94
pubmed: 19438456
J Dermatol. 2018 Sep;45(9):1031-1043
pubmed: 29863806
J Drugs Dermatol. 2017 Nov 1;16(11):s135-s140
pubmed: 29141068
J Clin Epidemiol. 2000 Jan;53(1):1-12
pubmed: 10693897
An Bras Dermatol. 2017 Jan-Feb;92(1):35-40
pubmed: 28225954
J Eur Acad Dermatol Venereol. 2018 Jan;32(1):11-22
pubmed: 29178529
Br J Dermatol. 2010 Apr;162(4):843-7
pubmed: 20105167
Br J Dermatol. 2009 Mar;160(3):629-32
pubmed: 19016703
Br J Dermatol. 2003 Dec;149(6):1207-13
pubmed: 14674898
Br J Dermatol. 2001 Jul;145(1):95-9
pubmed: 11453914
J Behav Exp Econ. 2015 Feb;54:10-21
pubmed: 28713668
J Am Acad Dermatol. 2012 Mar;66(3):e97-102
pubmed: 21601948
Dermatol Ther. 2020 Jul;33(4):e13799
pubmed: 32520416
J Eur Acad Dermatol Venereol. 2019 Mar;33(3):608-611
pubmed: 30394586